Pabitrakumar Bhattacharyya
#961Managing Director
54
Age
30y
Exp
2y
Tenure
4/10
Risk
🎓 B. Tech Chemical · UDCT
🏛️ None
CompensationTBP
Personality
5
Open
6
Cons
4
Extr
5
Agre
4
Neur
Unichem Labs.
Healthcare · Small Cap
Distressed / Turnaround · Hierarchical
About
Pabitrakumar Bhattacharyya is the Managing Director of Unichem Labs., a Small Cap company in the Healthcare sector with a market cap of ₹2K Cr. A Pragmatic leader with 30 years of experience, he is known for data-driven decision-making and organic builder strategy. Maintains a low-profile, focused approach to navigating the generic pharmaceuticals space with a emphasis on regulatory compliance and stable output.
FAQ
What is Pabitrakumar Bhattacharyya's leadership style?
Pabitrakumar Bhattacharyya is classified as a Pragmatic leader. He is data-driven in decision-making, with a shareholder champion motivation and steady-marathon pace of execution.
What is Pabitrakumar Bhattacharyya's educational background?
Pabitrakumar Bhattacharyya holds a B. Tech Chemical from UDCT.
Who is the CEO of Unichem Labs.?
Pabitrakumar Bhattacharyya is the Managing Director of Unichem Labs.. He has been with the company for 2 years and in the current role for 2 years.
Leadership DNA
ArchetypePragmatic
MotivationShareholder Champion
CrisisSteady Hand
DecisionData-Driven
GrowthOrganic Builder
PeopleInstitution Builder
InnovationTraditionalist
PaceSteady-Marathon
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployerSteady Employer
BrandValue-Champion
FocusOperational Excellence
OrientationDeep Specialist
Leadership Evidence
“Maintains a low-profile, focused approach to navigating the generic pharmaceuticals space with a emphasis on regulatory compliance and stable output.”
⚡ Crisis●●●●○
Maintained operational continuity and stability during the company's transition and regulatory challenges.
🎯 Motivation●●●●○
Focused on value preservation and consistent performance within the mature pharmaceutical landscape.
👥 People●●●○○
Emphasizes long-term organizational stability and process adherence over rapid disruption.
📈 Growth●●●●○
Prioritizes internal efficiencies and steady product portfolio management over high-risk acquisitions.
💡 Innovation●●●●○
The company focuses on a legacy portfolio of generic formulations and API manufacturing rather than pioneering new drug discovery.
🏃 Pace●●●○○
The business operates on a predictable, process-driven manufacturing cycle typical of mid-sized generic pharmaceutical companies.
🌱 Purpose●●●○○
As a legacy pharma player currently in a turnaround phase, its primary institutional focus is on operational efficiency and debt reduction rather than ESG leadership.
🏷️ Brand●●●○○
The company's market position is built on providing affordable generic healthcare solutions, emphasizing cost-competitiveness over premium branding.
🤝 Customer●●●●○
Unichem primarily operates through B2B channels, selling bulk drugs and formulations to other pharmaceutical companies and institutional distributors.
💼 Employer●●●○○
The company is viewed as a legacy institution providing stable, traditional roles within the manufacturing and pharmaceutical supply chain sector.
📋 Mandate
Following recent acquisition activity and legacy challenges, the company requires a mandate to stabilize finances and streamline the portfolio.
🏢 Culture●●●○○
Legacy pharma business undergoing turnaround; structure remains formal and process-driven typical of established manufacturing entities.
Financials
Revenue FY25₹2K Cr
PAT FY25₹138 Cr
Rev CAGR 5Y18.3%
OPM6.8%
NPM6.7%
ROE5.6%
ROCE5.4%
P/E7.7
Fwd P/E—
P/B0.9
D/E20.6
Promoter71.3%
Institutional10%
Mkt Cap₹2K Cr
Compensation
To Be Published
Data being verified from audited reports
